DEDHAM, Mass. — Qlaris Bio, Inc. announced the appointment of Robert Warner to its board of directors as the clinical-stage biotechnology company advances its lead glaucoma program into late-stage development.
Warner is an experienced life sciences executive and board member with a background in corporate strategy, financing, and company building across the biotechnology and healthcare sectors. His appointment comes as Qlaris Bio continues to move QLS-111, its lead investigational therapy for glaucoma, through late-stage clinical trials.
Warner has supported companies through multiple phases of growth, including clinical development, capital formation, and strategic transactions. He currently serves on the boards of several biotechnology and medical device companies and has held senior leadership and advisory roles across the life sciences industry, including serving as President, North America, at Alcon.
“Robert’s experience as a global commercial leader in ophthalmology will be an important asset as Qlaris continues to advance QLS-111 through our next phase of clinical development,” said Thurein Htoo, Chief Executive Officer of Qlaris Bio. “We are thrilled to welcome him to our board and look forward to his strategic insight during the company’s next stage of growth.”
“I’m excited to join the Qlaris Bio board at such a pivotal time for the company,” Warner said. “The team has made impressive progress advancing a truly differentiated approach to glaucoma treatment, and I look forward to supporting the company’s mission and long-term growth.”
